Evidence map›Paper›PMID 29359026›Full record

ArticleWorld journal of diabetes2018

Short-term effects of obestatin on hexose uptake and triacylglycerol breakdown in human subcutaneous adipocytes.

Christian Carpéné, Francisco Les, David Estève, Jean Galitzky

Open access · diamondAbstract read
In one paragraph

Article in World journal of diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 3 countries.

Christian CarpénéInstitut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, Université Paul Sabatier, Toulouse 31432, France. christian.carpene@inserm.fr.
Francisco LesDepartment of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego 50830, Spain.
David EstèveInstitut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, Université Paul Sabatier, Toulouse 31432, France.
Jean GalitzkyInstitut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale, Université Paul Sabatier, Toulouse 31432, France.
Creative Research Enterprises (United States) · USInserm · FRInstitut des Maladies Métaboliques et Cardiovasculaires · FRUniversidad San Jorge · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study complete dose-dependent effects of obestatin on lipolytic and glucose transport activities in human adipocyte preparations highly responsive to insulin.

methodsAdipocytes were prepared by liberase digestion from subcutaneous abdominal adipose tissue obtained from overweight subjects undergoing plastic surgery. The index of lipolytic activity was the glycerol released in the incubation medium, while glucose transport was assessed by [

resultsWhen tested from 0.1 nmol/L to 1 μmol/L, obestatin did not stimulate glycerol release; it did not inhibit the lipolytic effect of isoprenaline and did not alter the insulin antilipolytic effect. Obestatin hardly activated glucose transport at 1 μmol/L only. Moreover, the obestatin stimulation effect was clearly lower than the threefold increase induced by insulin 100 nmol/L.

conclusionLow doses of obestatin cannot directly influence lipolysis and glucose uptake in human fat cells.

Indexed as

AdipokinesGlucose uptakeHuman adipocytesInsulinLipolysisObestatin

Identifiers

PMID29359026
PMCPMC5763037
OpenAlexW2784283535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.